Members Wealth LLC Invests $864,000 in DiaMedica Therapeutics, Inc. $DMAC

Members Wealth LLC purchased a new position in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 101,382 shares of the company’s stock, valued at approximately $864,000. Members Wealth LLC owned approximately 0.19% of DiaMedica Therapeutics as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Cooperman Leon G grew its stake in shares of DiaMedica Therapeutics by 98.2% during the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock worth $22,463,000 after acquiring an additional 1,619,761 shares in the last quarter. Corient IA LLC bought a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $910,000. Paragon Associates & Paragon Associates II Joint Venture grew its stake in shares of DiaMedica Therapeutics by 34.6% during the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock worth $6,011,000 after acquiring an additional 225,000 shares in the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $687,000. Finally, Invesco Ltd. bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $54,000. 10.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DMAC. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Trading Down 3.9%

NASDAQ DMAC opened at $6.22 on Friday. The company has a market cap of $335.13 million, a PE ratio of -8.89 and a beta of 1.16. DiaMedica Therapeutics, Inc. has a 12 month low of $3.47 and a 12 month high of $10.42. The stock has a 50 day moving average of $7.24 and a 200-day moving average of $7.59.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of ($0.03) million during the quarter, compared to analyst estimates of $13.50 million. As a group, sell-side analysts predict that DiaMedica Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.